Curis, Inc. Reports $32.8 Million Net Loss and No Revenue for Q2 2026

Curis, Inc. reported a net loss of $32.8 million for the six months ended June 30, 2026, compared to a net loss of $19.2 million for the same period in 2025, marking a 71% increase in losses. The company did not generate any revenue during the second quarter of 2026, a significant decline from $2.7 million in revenue for the same quarter in 2025. This drop in revenue is attributed to the cessation of royalty income following the sale of its drug Erivedge in November 2025. Operating expenses for the first half of 2026 totaled $21.5 million, down from $23.5 million in the prior year, primarily due to reduced research and development costs.

In terms of operational metrics, Curis has focused its efforts on the development of emavusertib, an investigational drug for various cancers. The company is currently conducting clinical trials, including a Phase 2 study of emavusertib in combination with zanubrutinib for chronic lymphocytic leukemia (CLL) and a Phase 1/2 study for relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with ibrutinib. As of June 30, 2026, Curis had cash and cash equivalents of $5.1 million, which, along with the estimated net proceeds of approximately $4.8 million from a public offering completed in August 2026, is expected to fund operations into the fourth quarter of 2026.

The company has undergone significant changes in its capital structure, including a reverse stock split and the issuance of new shares through various financing rounds. In January 2026, Curis raised approximately $18.6 million through a private investment in public equity (PIPE) financing, which included the issuance of preferred stock and warrants. The company has also increased its authorized shares of common stock to 567.5 million, allowing for greater flexibility in future capital raises.

Curis continues to face substantial challenges, including the need for additional funding to support its research and development programs. The company has indicated that it may need to seek further financing through equity offerings or strategic collaborations. The ongoing development of emavusertib is critical to Curis's future, and the company has acknowledged that it may not achieve profitability in the foreseeable future. The management has expressed concerns about its ability to continue as a going concern, emphasizing the importance of securing additional capital to sustain operations and advance its clinical programs.